Linezolid treats cSSSI caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae. It’s particularly useful when other antibiotics fail.
Consider linezolid for patients with cSSSI showing signs of significant infection spread, such as cellulitis extending beyond the initial site or signs of systemic involvement (fever, chills, hypotension).
Remember: Linezolid is a reserve antibiotic. Prior antibiotic susceptibility testing is strongly recommended to guide treatment choices and prevent unnecessary resistance development. Always follow local guidelines for antibiotic stewardship.
Specific situations benefiting from linezolid include infections involving deep tissues (e. g., necrotizing fasciitis) or those in immunocompromised individuals where a rapid, potent response is crucial. However, assess the patient’s overall health and potential risks carefully before prescribing.
Monitor patients closely for side effects, such as bone marrow suppression (thrombocytopenia, anemia, leukopenia) and peripheral neuropathy. Regular blood counts are necessary during treatment. Adjust dosage based on renal function.
Alternative treatments should be explored if possible, given linezolid’s potential side effects and the risk of resistance development. Closely evaluate clinical response to assess treatment efficacy and modify treatment accordingly.
